GO:0004875 complement receptor activity: Mechanism, Genes

Complement receptor activity (GO:0004875) is a molecular function that enables a cell to bind any component or product of the complement cascade and transmit a signal across the membrane, initiating a change in cell activity. This activity is fundamental to innate and adaptive immunity, as it allows cells to sense complement deposition on pathogens or altered self-tissues and respond with effector functions such as phagocytosis, cytokine release, and cell migration [1, 6]. The complement system comprises over 30 proteins, and its activation products serve as ligands for a diverse array of receptors that are expressed on immune cells, including macrophages, neutrophils, B cells, and dendritic cells, as well as on non-immune cells like podocytes and astrocytes [1, 7]. Researchers study complement receptor activity to understand how the immune system discriminates between self and non-self, how complement contributes to tissue homeostasis, and how dysregulation leads to inflammatory and autoimmune diseases [1, 4, 5]. The receptors are attractive drug targets because they modulate key pathogenic pathways in conditions such as ANCA-associated vasculitis, lupus nephritis, and age-related macular degeneration [4, 5]. Moreover, complement receptors serve as entry points for certain pathogens, and their activity can be exploited or blocked for therapeutic benefit [1, 6]. Advances in structural biology have revealed the molecular basis of ligand recognition and signaling for several complement receptors, providing a framework for rational drug design. Concurrently, CRISPR gene editing technologies allow precise manipulation of receptor genes in cell models, enabling causal interrogation of their functions in health and disease. This article integrates authoritative QuickGO annotation data with verified PubMed literature to provide a comprehensive overview of complement receptor activity, its mechanisms, key genes, and research methodologies.

According to the Gene Ontology, complement receptor activity (GO:0004875) is defined as combining with any component or product of the complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. This definition encompasses both the ligand-binding event and the downstream signal transduction that alters cellular behavior. The synonym anaphylatoxin receptor activity reflects the subset of receptors that bind complement anaphylatoxins such as C3a and C5a [1, 6].

Complement receptor activity is essential for immune surveillance and host defense, as it enables cells to recognize complement-opsonized pathogens and damaged cells, thereby triggering clearance and inflammatory responses. Dysregulation of this activity contributes to the pathogenesis of autoimmune diseases, including ANCA-associated vasculitis and lupus nephritis, where autoantibodies or excessive complement activation drive tissue damage [4, 5]. Furthermore, complement receptors influence adaptive immunity by modulating B cell activation and antigen presentation, linking innate and adaptive responses [3, 6]. Understanding complement receptor activity at the molecular level is therefore critical for developing targeted therapies that can selectively enhance or inhibit specific receptor functions without compromising overall immune competence [1, 7].

The following genes encode the major receptors and associated proteins that mediate complement receptor activity (GO:0004875).

Complement receptor activity is regulated at multiple levels. Expression levels of receptors are controlled by transcriptional and post-transcriptional mechanisms in response to inflammatory cytokines and microbial products. For example, C5aR1 is upregulated on neutrophils upon exposure to lipopolysaccharide or tumor necrosis factor-alpha. Receptor desensitization and internalization following ligand binding are mediated by G-protein-coupled receptor kinases and beta-arrestins, which terminate signaling. Soluble and membrane-bound complement regulators, such as factor H, C4b-binding protein, CD46, CD55, and CD59, modulate ligand availability and protect host tissues from complement attack. Additionally, crosstalk with other signaling pathways, including those downstream of Fc receptors and Toll-like receptors, can amplify or dampen complement receptor responses. These regulatory mechanisms ensure that complement receptor activity is appropriately balanced to fight infection without causing excessive tissue damage.

ANCA-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation of small blood vessels. C5a and its receptor C5aR1 play a central role in AAV pathogenesis by priming neutrophils for activation by ANCA, leading to tissue damage. Low concentrations of C5a complement receptor antibodies are linked to disease activity and relapse in AAV, suggesting that autoantibodies against C5aR1 may modulate disease course. Targeting C5aR1 with inhibitors such as avacopan has shown clinical benefit in AAV, underscoring the therapeutic relevance of complement receptor activity.

Lupus nephritis is a serious complication of systemic lupus erythematosus, driven by immune complex deposition and complement activation. The complement receptor of the immunoglobulin superfamily (VSIG4) reduces murine lupus nephritis and cutaneous disease, indicating a protective role for this receptor in autoimmunity. VSIG4 likely mediates clearance of C3b-opsonized immune complexes and modulates inflammatory responses, highlighting how complement receptor activity can influence disease outcomes.

Complement receptors are exploited by various pathogens for cell entry, and they also mediate inflammatory responses that can be detrimental in sepsis and acute lung injury. For instance, C5aR1 signaling contributes to neutrophil dysfunction and organ damage in sepsis. Understanding the balance between protective and pathogenic complement receptor activity is essential for developing therapies that preserve host defense while limiting tissue injury [1, 6].

Flow cytometry is widely used to measure surface expression of complement receptors on immune cells and to assess ligand binding using fluorescently labeled complement proteins or antibodies. For example, binding of C3b or iC3b to CR1 or CR3 can be quantified by flow cytometry, and competition assays can determine affinity and specificity. This method is essential for phenotyping receptor expression in health and disease.

Phagocytosis assays using complement-opsonized particles (e.g., sheep erythrocytes coated with C3b/iC3b) measure the uptake capacity of phagocytes expressing complement receptors. Chemotaxis assays, such as Transwell migration, assess the ability of cells to migrate toward C3a or C5a gradients. These functional readouts directly reflect complement receptor activity and are used to evaluate the impact of genetic modifications or therapeutic inhibitors.

X-ray crystallography and cryo-electron microscopy have provided high-resolution structures of complement receptors and their complexes with ligands, revealing the molecular determinants of binding and signaling. Surface plasmon resonance and isothermal titration calorimetry are used to measure binding kinetics and affinities. These techniques inform the design of small molecules or antibodies that modulate receptor activity.

CRISPR knockout screens can identify genes that regulate complement receptor activity or that are required for downstream signaling. For example, a genome-wide knockout screen in macrophages challenged with complement-opsonized particles can reveal novel regulators of phagocytosis. Similarly, CRISPR activation screens can uncover genes whose overexpression enhances or inhibits receptor function. These approaches are powerful for discovering new therapeutic targets.

Researchers studying complement receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation in relevant cell models, from knockout to knock-in and overexpression, as well as library screening and bioinformatics support.

Complement receptor activity (GO:0004875) is a cornerstone of immune recognition and response, enabling cells to detect complement-opsonized targets and initiate appropriate effector functions. The diversity of receptors and their ligands allows for nuanced regulation of inflammation, pathogen clearance, and adaptive immunity [6, 7]. Dysregulation of these receptors contributes to autoimmune and inflammatory diseases, making them attractive therapeutic targets [4, 5]. Advances in CRISPR gene editing and structural biology are accelerating our understanding of complement receptor mechanisms and facilitating the development of precision therapeutics [7, 8]. Continued research into this molecular function promises to yield new insights and treatments for complement-mediated disorders.